Aging in HIV-Infected Subjects: A New Scenario and a New View

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2018 Feb 13

PMID 29430462

Citations 29

Authors

Eugenia Negredo

David Back

Jose-Ramon Blanco

Julia Blanco

Kristine M Erlandson

Maite Garolera

Giovanni Guaraldi

Patrick Mallon

Jose Molto

Jose Antonio Serra

Bonaventura Clotet

Affiliations

Soon will be listed here.

Abstract

The prevalence of HIV-infected people aged 50 years or older is increasing rapidly; the proportion will increase from 28% to 73% in 2030. In addition, HIV-infected individuals may be more vulnerable to age-related condition. There is growing evidence that the prevalence of comorbidities and other age-related conditions (geriatric syndromes, functional or neurocognitive/mental problems, polypharmacy, and social difficulties) is higher in the HIV-infected population than in their uninfected counterparts. However, despite the potential impact of this situation on health care, little information exists about the optimal clinical management of older HIV-infected people. Here we examine the age-related conditions in older HIV-infected persons and address clinical management according to author expertise and published literature. Our aim is to advance the debate about the most appropriate management of this population, including less well-studied aspects, such as frequency of screening for psychological/mental and social and functional capabilities.

Citing Articles

Preference for care models among older people living with HIV: cross-sectional study.

Li M, Ren J, Luo Y, Watson R, Zheng Y, Ding L BMC Public Health. 2023; 23(1):2033.

PMID: 37853369 PMC: 10585841. DOI: 10.1186/s12889-023-16941-9.

Involvement of lncRNA TUG1 in HIV-1 Tat-Induced Astrocyte Senescence.

Pillai P, Kannan M, Sil S, Singh S, Thangaraj A, Chivero E Int J Mol Sci. 2023; 24(5).

PMID: 36901763 PMC: 10002460. DOI: 10.3390/ijms24054330.

Identifying the needs of older people living with HIV (≥ 50 years old) from multiple centres over the world: a descriptive analysis.

Grosso T, Hernandez-Sanchez D, Dragovic G, Vasylyev M, Saumoy M, Blanco J AIDS Res Ther. 2023; 20(1):10.

PMID: 36782210 PMC: 9924192. DOI: 10.1186/s12981-022-00488-7.

Role of Autophagy in HIV-1 and Drug Abuse-Mediated Neuroinflammaging.

Sil S, Thangaraj A, Oladapo A, Hu G, Kutchy N, Liao K Viruses. 2023; 15(1).

PMID: 36680084 PMC: 9866731. DOI: 10.3390/v15010044.

HIV-Associated Conditions in Older Adults.

Jaqua E, Labib W, Danji K Cureus. 2023; 14(12):e32661.

PMID: 36660505 PMC: 9844266. DOI: 10.7759/cureus.32661.

References

John M, Greene M, Hessol N, Zepf R, Parrott A, Foreman C . Geriatric Assessments and Association With VACS Index Among HIV-Infected Older Adults in San Francisco. J Acquir Immune Defic Syndr. 2016; 72(5):534-41. PMC: 4942400. DOI: 10.1097/QAI.0000000000001009. View

Worm S, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F . Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2009; 201(3):318-30. DOI: 10.1086/649897. View

Pilotto A, Cella A, Pilotto A, Daragjati J, Veronese N, Musacchio C . Three Decades of Comprehensive Geriatric Assessment: Evidence Coming From Different Healthcare Settings and Specific Clinical Conditions. J Am Med Dir Assoc. 2017; 18(2):192.e1-192.e11. DOI: 10.1016/j.jamda.2016.11.004. View

Franceschi C, Campisi J . Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014; 69 Suppl 1:S4-9. DOI: 10.1093/gerona/glu057. View

Edelman E, Gordon K, Glover J, McNicholl I, Fiellin D, Justice A . The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013; 30(8):613-28. PMC: 3715685. DOI: 10.1007/s40266-013-0093-9. View

Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D . HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013; 61(5):511-23. DOI: 10.1016/j.jacc.2012.06.063. View

Fried L, Tangen C, Walston J, Newman A, Hirsch C, Gottdiener J . Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56(3):M146-56. DOI: 10.1093/gerona/56.3.m146. View

Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M . Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011; 53(11):1130-9. DOI: 10.1093/cid/cir626. View

Gubavu C, Prazuck T, Niang M, Buret J, Mille C, Guinard J . Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. J Antimicrob Chemother. 2015; 71(4):1046-50. PMC: 4790618. DOI: 10.1093/jac/dkv430. View

10.

Wyatt C, Winston J, Malvestutto C, Fishbein D, Barash I, Cohen A . Chronic kidney disease in HIV infection: an urban epidemic. AIDS. 2007; 21(15):2101-3. DOI: 10.1097/QAD.0b013e3282ef1bb4. View

11.

Bierman A . Functional status: the six vital sign. J Gen Intern Med. 2001; 16(11):785-6. PMC: 1495293. DOI: 10.1111/j.1525-1497.2001.10918.x. View

12.

Piggott D, Erlandson K, Yarasheski K . Frailty in HIV: Epidemiology, Biology, Measurement, Interventions, and Research Needs. Curr HIV/AIDS Rep. 2016; 13(6):340-348. PMC: 5131367. DOI: 10.1007/s11904-016-0334-8. View

13.

Perez-Molina J, Rubio R, Rivero A, Pasquau J, Suarez-Lozano I, Riera M . Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority.... Lancet Infect Dis. 2015; 15(7):775-84. DOI: 10.1016/S1473-3099(15)00097-3. View

14.

Greene M, Covinsky K, Astemborski J, Piggott D, Brown T, Leng S . The relationship of physical performance with HIV disease and mortality. AIDS. 2014; 28(18):2711-9. PMC: 4380225. DOI: 10.1097/QAD.0000000000000507. View

15.

Erlandson K, Allshouse A, Jankowski C, Duong S, MaWhinney S, Kohrt W . Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials. 2012; 13(6):324-34. PMC: 4379206. DOI: 10.1310/hct1306-324. View

16.

Levett T, Cresswell F, Malik M, Fisher M, Wright J . Systematic Review of Prevalence and Predictors of Frailty in Individuals with Human Immunodeficiency Virus. J Am Geriatr Soc. 2016; 64(5):1006-14. DOI: 10.1111/jgs.14101. View

17.

Deeks S . HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2010; 62:141-55. PMC: 3759035. DOI: 10.1146/annurev-med-042909-093756. View

18.

Blanco J, Whitlock G, Milinkovic A, Moyle G . HIV integrase inhibitors: a new era in the treatment of HIV. Expert Opin Pharmacother. 2015; 16(9):1313-24. DOI: 10.1517/14656566.2015.1044436. View

19.

Gallagher P, Ryan C, Byrne S, Kennedy J, OMahony D . STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008; 46(2):72-83. DOI: 10.5414/cpp46072. View

20.

Goulet J, Fultz S, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M . Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity?. Clin Infect Dis. 2008; 45(12):1593-601. PMC: 3687553. DOI: 10.1086/523577. View